Novel systemic therapy options for hepatocellular carcinoma

Area of Science:

• Hepatology
• Medical Oncology

Background:

• Hepatocellular carcinoma (HCC) incidence is rising globally, particularly in the US, linked to Hepatitis C viral (HCV) infection.
• Liver cirrhosis is a common precursor to HCC, and current treatments like tumor resection offer limited curative potential.
• Effective systemic treatments for non-resectable HCC are lacking due to complications from liver cirrhosis.

Purpose of the Study:

• To review the challenges and current status of systemic therapy for Hepatocellular Carcinoma (HCC).
• To explore potential strategies for improving treatment outcomes in non-resectable HCC.
• To highlight the need for novel therapeutic approaches and clinical trials.

Main Methods:

• Literature review of existing studies on Hepatocellular Carcinoma (HCC) treatment.
• Analysis of challenges in systemic therapy design for HCC patients with liver cirrhosis.
• Evaluation of past and potential future treatment modalities.

Main Results:

• Orthotopic liver transplantation (OLT) offers long-term survival for selected HCC patients.
• Adjuvant therapies post-resection include interferon, polyprenoic acid, and immunotherapy.
• Aggressive chemotherapy regimens yield median survival times of only 3-5 months.

Conclusions:

• Systemic therapy for HCC is an ongoing area of research.
• Combining chemotherapy with angiogenesis inhibitors may offer a promising strategy.
• Further clinical trials are essential to develop effective treatments for non-resectable HCC.